The accuracy of skin self-examination for atypical nevi

Epidemiology

Volumn 7, Issue 6, 1996, Pages 619-623

  Titus Ernstoff, Linda ^a   Thörn, Magnus ^b   Tosteson, Tor D ^a   Brahme, Eva Månsson ^c   Yuen, Jonathan ^b   Baron, John A ^a,b   Adami, Hans Olov ^b,d  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d HARVARD CENTER FOR CANCER PREVENTION   (United States)

Author keywords

gender; pigmented nevus; population survey; prevalence; screening

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; NEVUS; PHOTOGRAPHY; PRIORITY JOURNAL; QUESTIONNAIRE; SELF EXAMINATION; SELF REPORT; SKIN EXAMINATION; SWEDEN;

EID: 0029851743     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001648-199611000-00009     Document Type: Article

References (32)

1. Devesa SS, Silverman DT, Young JL Jr, Pollack ES, Brown CC, Horn JW, Percy CL, Myers MH, McKay FW, Fraumeni JF Jr. Cancer incidence and mortality trends among whites in the United States, 1947-84. J Natl Cancer Inst 1987;79:701-770.
2. Thorn M, Bergstrom R, Adami H-O, Ringborg U. Trends in the incidence of malignant melanoma in Sweden, by anatomic site, 1960-1984. Am J Epidemiol 1990;132:1066-1077.
3. van der Esch EP, Muir CS, Nectoux J, Macfarlane G, Maisonneuve P, Bharucha H, Briggs J, Cooke RA, Dempster AG, Essex WB, Hofer PA, Hood AF, Ironside P, Larsen TE, Little JH, Philipps R, Pfau RS, Prade M, Pozharisski KM, Rilke F, Schafler K. Temporal change in diagnostic criteria as a cause of the increase of malignant melanoma over time is unlikely. Int J Cancer 1991;47:483-489.
4. Thorn M, Ponten F, Bergstrom R, Sparen P, Adami H-O. Trends in tumor characteristics and survival of malignant melanoma 1960-1984: a population-based study in Sweden. Br J Cancer 1994;70:743-748.
5. Thorn M, Sparen P, Bergstrom R, Adami H-O. Trends in mortality rates from malignant melanoma in Sweden 1953-1987 and forecasts up to 2007. Br J Cancer 1992;66:563-567.
6. Venzon D, Moolgavkar SH. Cohort analysis of malignant melanoma in five countries. Am J Epidemiol 1984;119:62-70.
7. Roush GC, Schymura MJ, Holford TR. Patterns of invasive melanoma in the Connecticut Tumor Registry: is the long-term increase real? Cancer 1988;61:2586-2589.
8. Clark WH Jr, Elder DE, Guerry DIV, Epstein M, Greene MH, Van Horn M. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984;15:1147-1165.
9. Shaw HM, McCarthy WH, McCarthy SW, Milton GW. Thin malignant melanomas and recurrence potential. Arch Surg 1987;122:1147-1150.
10. Tiersten AD, Grin CM, Kopf AW, Gottlieb GJ, Bart RS, Rigel DS, Friedman RJ, Levenstein MJ. Prospective follow-up for malignant melanoma in patients with atypical-mole (dysplastic nevus) syndrome. J Dermatol Surg Oncol 1991;17:44-48.
11. Schneider JS, Moore DH II, Sagebiel RW. Risk factors for melanoma incidence in prospective follow-up: the importance of atypical (dysplastic) nevi. Arch Dermatol 1994;130:1002-1007.
12. Kang S, Barnhill RL, Mihm MC, Mihm MC Jr, Fitzpatrick TB, Sober AJ. Melanoma in individuals with clinically atypical nevi. Arch Dermatol 1994;130:999-1001.
13. Marghoob AA, Kopf, Rigel DS, Bart RS, Friedman RJ, Yadav S, Abadir M, Sanfilippo L, Silverman MK, Vossaert KA. Risk of cutaneous malignant melanoma in patients with "classic" atypical-mole syndrome. Arch Dermatol 1994;130:993-998.
14. Titus-Ernstoff L, Duray PH, Ernstoff MS, Barnhill RL, Horn PL, Kirkwood JM. Dysplastic nevi in association with multiple primary melanoma. Cancer Res 1988;48:1016-1018.
15. Duray PH, Ernstoff MS. Dysplastic nevus in histologic contiguity with acquired nonfamilial melanoma. Arch Dermatol 1987;123:80-84.
16. Nordlund JJ, Kirkwood J, Forget BM, Scheibner A, Albert DM, Lerner E, Milton GW. Demographic study of clinically atypical (dysplastic) nevi in , patients with melanoma and comparison subjects. Cancer Res 1985;45: 1855-1861.
17. Holly EA, Kelly JW, Shpall SN. Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol 1987;17:459-468.
18. Halpern AC, Guerry D, Elder DE, Clark WH Jr, Synnestvedt M, Norman S, Ayerle R. Dysplastic nevi as risk markets of sporadic (nonfamilial) melanoma. Arch Dermatol 1991;127:995-999.
19. Augustsson A, Stierner U, Rosdahl I, Suurküla M. Common and dysplastic naevi as risk factors for cutaneous malignant melanoma in a Swedish population. Acta Derm Venereol 1991;71:518-524.
20. Tosteson TD, Titus-Ernstoff L, Baron JA, Karagas MR. A two-staged validation study for determining sensitivity and specificity. Environ Health Perspect 1994;102(suppl 8):11-14.
21. Little JA, Rubin DB. Statistical Analysis with Missing Data. New York: John Wiley and Sons, 1987.
22. Titus-Ernstoff L, Bamhill RL, Duray PH, Ernstoff M, Kirkwood JM. Dysplastic nevi in relation to superficial spreading melanoma. Cancer Epidemiol Biomarkers Prev 1993;2:99-101.
23. Thorn M, Adami H-O, Ringborg U, Bergstrom R, Krusemo U. The association between anatomic site and survival in malignant melanoma: an analysis of 12,353 cases from the Swedish Cancer Registry. Eur J Cancer Clin Oncol 1989;25:483-491.
24. Augustsson A, Stierner U, Suurküla M, Rosdahl I. Prevalence of common and dysplastic naevi in a Swedish population. Br J Dermatol 1991;124:152-156.
25. Dubin N, Moseson M, Pasternack BS. Epidemiology of malignant melanoma: pigmentary traits, ultraviolet radiation, and the identification of high-risk populations. Recent Results Cancer Res 1986;102:56-75.
26. Little P, Keefe M, White J. Self screening for risk of melanoma: validity of self mole counting by patients in a single general practice. BMJ 1995;310: 912-916.
27. Lawson DD, Moore DH, Schneider JS, Sagebiel RW. Nevus counting as a risk factor for melanoma: comparison of self-count with count by physician. J Am Acad Dermatol 1994;31:438-444.
28. Doherty VR, MacKie RM. Experience of a public education programme on early detection of cutaneous malignant melanoma. BMJ 1988;297:388-391.
29. Graham-Brown RAC, Osborne JE, London SP, Fletchet A, Shaw D, Williams B, Bowry V. The initial effects on workload and outcome of a public education campaign on early diagnosis and treatment of malignant melanoma in Leicestershire. Br J Dermatol 1990;122:53-59.
30. Masri GD, Clark WH Jr, Guerry D IV, Halpern A, Thompson J, Elder DE. Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease. J Am Acad Dermatol 1990;22:1042-1048.
31. Berwick M, Begg CB, Fine JA, Roush GC, Barnhill RL. Screening for cutaneous melanoma by skin self-examination. J Natl Cancer Inst 1996;88: 17-23.
32. Koh HK, Miller DR, Geller AC, Clapp RW, Mercer MB, Lew RA. Who discovers melanoma? J Am Acad Dermatol 1992;26:914-919.